Literature DB >> 22064563

Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey.

Donald B Bailey1, Melissa Raspa, Ellen Bishop, Murrey Olmsted, Usha G Mallya, Elizabeth Berry-Kravis.   

Abstract

OBJECTIVE: To identify the most common neurological and behavioral symptoms treated by medications in individuals with fragile X syndrome (FXS), factors associated with treatment variability, and difficulty in swallowing a pill.
METHOD: A total of 1019 caregivers provided information about 1064 sons and 299 daughters with FXS in a US national survey. Caregivers reported (a) current use of medications for attention, anxiety, hyperactivity, mood swings, anger, depression, seizures, self-injury, or sleep; (b) perceived efficacy; and (c) difficulty in swallowing a pill.
RESULTS: Sixty-one percent of males and 38% of females were currently taking medication for at least 1 symptom. The most common symptoms were anxiety, attention, and hyperactivity. Treatments for attention and hyperactivity were common in childhood but declined substantially after the age of 18 years; anxiety treatment remained high in adults. Children perceived to be more impaired and children diagnosed or treated for autism were more likely to be taking medications. Caregivers considered most medications somewhat effective, but less than one-third rated current medication as "a lot" effective. Many children had difficulty swallowing a pill, but only 11% of adult males and 2% of adult females had a lot of difficulty.
CONCLUSION: Symptom-based medication use is common in FXS, although response is incomplete and there is clearly an unmet need for medications with improved efficacy. The persistent use of medications to treat anxiety, mood, and behavior problems throughout adolescence and into the adult years suggests important outcomes when evaluating the efficacy of new medications.

Entities:  

Mesh:

Year:  2012        PMID: 22064563     DOI: 10.1097/DBP.0b013e318236c0e1

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  22 in total

1.  Prevalence and Predictors of Anxiety Disorders in Adolescent and Adult Males with Autism Spectrum Disorder and Fragile X Syndrome.

Authors:  Jordan Ezell; Abigail Hogan; Amanda Fairchild; Kimberly Hills; Jessica Klusek; Leonard Abbeduto; Jane Roberts
Journal:  J Autism Dev Disord       Date:  2019-03

2.  Longitudinal trajectories of aberrant behavior in fragile X syndrome.

Authors:  Kristin M Hustyi; Scott S Hall; Booil Jo; Amy A Lightbody; Allan L Reiss
Journal:  Res Dev Disabil       Date:  2014-08-15

3.  Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.

Authors:  S J Bonasera; T R Chaudoin; E H Goulding; M Mittek; A Dunaevsky
Journal:  Genes Brain Behav       Date:  2017-03-29       Impact factor: 3.449

4.  Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.

Authors:  Walter E Kaufmann; Sharon A Kidd; Howard F Andrews; Dejan B Budimirovic; Amy Esler; Barbara Haas-Givler; Tracy Stackhouse; Catharine Riley; Georgina Peacock; Stephanie L Sherman; W Ted Brown; Elizabeth Berry-Kravis
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

Review 5.  Public Health Literature Review of Fragile X Syndrome.

Authors:  Melissa Raspa; Anne C Wheeler; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

6.  Medication use by adolescents and adults with fragile X syndrome.

Authors:  D J Laxman; J S Greenberg; L S DaWalt; J Hong; M G Aman; M Mailick
Journal:  J Intellect Disabil Res       Date:  2017-10-15

Review 7.  Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back.

Authors:  Christina Gross; Anne Hoffmann; Gary J Bassell; Elizabeth M Berry-Kravis
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

8.  Biobehavioral indicators of social fear in young children with fragile X syndrome.

Authors:  Bridgette L Tonnsen; Svetlana V Shinkareva; Sara C Deal; Deborah D Hatton; Jane E Roberts
Journal:  Am J Intellect Dev Disabil       Date:  2013-11

9.  The economic burden of fragile x syndrome: healthcare resource utilization in the United States.

Authors:  Patricia Sacco; Gorana Capkun-Niggli; Xin Zhang; Rosemary Jose
Journal:  Am Health Drug Benefits       Date:  2013-03

Review 10.  Molecular medicine of fragile X syndrome: based on known molecular mechanisms.

Authors:  Shi-Yu Luo; Ling-Qian Wu; Ran-Hui Duan
Journal:  World J Pediatr       Date:  2015-11-07       Impact factor: 2.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.